Zobrazeno 1 - 10
of 265
pro vyhledávání: '"osimertinib resistance"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the most applied targeted therapy for EGFR-mutant lung adenocarcinoma (LUAD). The third-generation EGFR-TKI, osimertinib, is widely used throughout lung cancer tre
Externí odkaz:
https://doaj.org/article/39ee13eba0734f14901c11e5583b3e95
Autor:
Xiaoqing Wang, Ju Zhu, Lingling Li, Qilin Zhao, Yutang Huang, Chunjie Wen, Dan Chen, Lanxiang Wu
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-16 (2024)
Abstract Background Patient-derived xenograft (PDX) is currently considered a preferred preclinical model to evaluate drug sensitivity, explore drug resistance mechanisms, and select individualized treatment regimens. Methods Histopathological examin
Externí odkaz:
https://doaj.org/article/0d7cbfbfabc24a318b9e68dfc9b72d47
Autor:
Jiaxin Liu, Lingyun Wei, Qing Miao, Sutong Zhan, Peilin Chen, Wei Liu, Liang Cao, Dong Wang, Hongbing Liu, Jie Yin, Yong Song, Mingxiang Ye, Tangfeng Lv
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-17 (2024)
Abstract Background Overcoming resistance to Osimertinib in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is clinically challenging because the underlying mechanisms are not fully understood. The murine double minu
Externí odkaz:
https://doaj.org/article/31df906818f147a696a9991a2c2ff3a1
Autor:
Jing Wang, Yuna Wang, Shuanggou Zhang, Yana Qu, Ruohan Zhang, Xuanjun Wang, Jun Sheng, Peiyuan Sun
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Epidermal growth factor receptor (EGFR)-activating mutations are critical factors in the development of EGFR-driven non-small-cell lung cancer (NSCLC), and molecular targeted therapies have focused on inhibiting these mutations. EGFR tyrosin
Externí odkaz:
https://doaj.org/article/5521709c7ffa459e87a5c49014de1df1
Autor:
Takuya Shintani, Yu-Ting Shun, Yuji Toyozumi, Kenji Ikemura, Takayuki Shiroyama, Izumi Nagatomo, Kentaro Jingushi, Yoshito Takeda, Atsushi Kumanogoh, Masahiro Okuda
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Overcoming resistance to epidermal growth factor receptor tyrosine kinase inhibitors, including osimertinib, is urgent to improve lung cancer treatment outcomes. Extracellular vesicle (EV)-derived microRNAs (EV-miRNAs) play important roles i
Externí odkaz:
https://doaj.org/article/84b94dfa07784919a9c1fcf233120a5a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposesOsimertinib, one of the third-generation EGFR-tyrosine kinase inhibitors (TKIs) designed to target EGFR T790M mutation, significantly improves the prognosis of lung cancer. However, drug resistance still happens and MET amplification is respo
Externí odkaz:
https://doaj.org/article/ed04fee8e41140f1a3aebca92697ae11
Autor:
Yi-fang Tang, Zheng-hua Liu, Lei-yi Zhang, Sheng-hao Shi, Shun Xu, Jin-An Ma, Chun-Hong Hu, Fang-wen Zou
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-19 (2024)
Abstract Background Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are involved in the occurrence and development of a variety of tumors. The aim of this study was to investigate the effects of cir
Externí odkaz:
https://doaj.org/article/812c91d0624f4f05bfe3667c5935fab9
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Osimertinib, a third-generation inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, exhibits remarkable efficacy in prolonging the survival of patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations, surpassing the
Externí odkaz:
https://doaj.org/article/c1396ec077534b76a08879082ca9e14f
Publikováno v:
MedComm, Vol 5, Iss 8, Pp n/a-n/a (2024)
Abstract Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in lung adenocarcinoma (LUAD), but the underlying mechanisms are still not fully understood. Cancer‐associated fibroblasts (CAFs) are the most abundant stro
Externí odkaz:
https://doaj.org/article/2df4f14e2be14d66a2ad6ce4316b5dfb
Autor:
Dandan Ding, Chenguang Xu, Jufeng Zhang, Ying Zhang, Lipeng Xue, Jingjing Song, Zhiming Luo, Xiaoyu Hong, Jian Wang, Weicheng Liang, Xingyang Xue
Publikováno v:
Translational Oncology, Vol 43, Iss , Pp 101895- (2024)
Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the preferred treatment for EGFR-mutated lung cancer. However, acquired resistance inevitably develops. While non-coding RNAs have b
Externí odkaz:
https://doaj.org/article/b562177394694bbca82342cf964d2e89